NCT07052695 2025-12-15Mosunetuzumab for CLL MRD ClearanceDana-Farber Cancer InstitutePhase 1/2 Recruiting40 enrolled
NCT03328078 2025-06-05CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)Curis, Inc.Phase 1/2 Recruiting152 enrolled
NCT02352558 2023-11-14A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic MalignanciesSumitomo Pharma America, Inc.Phase 1 Completed15 enrolled